Selecta is developing first-in-class integrated synthetic nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVP™) technology. These synthetic vaccines mimic the structure of natural pathogens with regards to size, shape and the sequence of immunological information for highly-effective targeting to immune cells to produce an optimal immune response. Selecta’s novel synthetic nanoparticle vaccines enable expanded opportunities for both the treatment and prevention of a wide range of human diseases including infectious, CNS, metabolic and inflammatory diseases.

Doug Cole is on the Board of Directors.